Savara (SVRA) Non-Current Debt (2015 - 2026)
Savara (SVRA) posted quarterly Non-Current Debt of $30.1 million for Q1 2026, up 1.84% year-over-year from $29.5 million in Q1 2025, and up 0.53% quarter-over-quarter from $29.9 million in Q4 2025.
Savara (SVRA) Non-Current Debt (2015 - 2026) Analysis & Trends
Savara (SVRA) has reported Non-Current Debt for 12 consecutive years, with $30.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Debt rose 1.84% year-over-year to $30.1 million; the TTM figure through Mar 2026 stood at $30.1 million (up 1.84% YoY), while the FY2025 annual figure was $29.9 million, up 12.35% from the prior year.
- Non-Current Debt improved to $30.1 million in Q1 2026 per SVRA's latest filing, from $29.9 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $30.1 million in Q1 2026 and bottomed at $13.3 million in Q1 2022.
- Historically, Non-Current Debt has averaged $26.5 million across 5 years, with a median of $26.4 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Debt sank 47.28% — and 2023, when it jumped 96.45%.
- Savara's Non-Current Debt stood at $26.1 million in 2022, then rose by 1.04% to $26.3 million in 2023, then grew by 1.03% to $26.6 million in 2024, then grew by 12.35% to $29.9 million in 2025, then climbed by 0.53% to $30.1 million in 2026.
- Business Quant data shows SVRA's Non-Current Debt at $30.1 million in Q1 2026, $29.9 million in Q4 2025, and $29.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 30.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.11 Mn |
| Mar 31, 2026 | 30.07 Mn |
| Dec 31, 2025 | 29.91 Mn |
| Sep 30, 2025 | 29.78 Mn |
| Jun 30, 2025 | 29.65 Mn |
| Mar 31, 2025 | 29.52 Mn |
| Dec 31, 2024 | 26.62 Mn |
| Sep 30, 2024 | 26.55 Mn |
| Jun 30, 2024 | 26.48 Mn |
| Mar 31, 2024 | 26.42 Mn |
| Dec 31, 2023 | 26.35 Mn |
| Sep 30, 2023 | 26.28 Mn |
| Jun 30, 2023 | 26.21 Mn |
| Mar 31, 2023 | 26.15 Mn |
| Dec 31, 2022 | 26.08 Mn |
| Sep 30, 2022 | 26.01 Mn |
| Jun 30, 2022 | 25.94 Mn |
| Mar 31, 2022 | 13.31 Mn |
| Dec 31, 2021 | 17.32 Mn |
| Sep 30, 2021 | 21.35 Mn |